A randomised trial in 650 patients has confirmed the safety and efficacy of a new second line treatment for metastatic colorectal cancer, researchers report at the ESMO Asia 2017 Congress. Oral fluorinated pyrimidines have been investigated to replace intravenous 5FU in colorectal cancer (CRC). Capecitabine combined with oxaliplatin (XELOX) has demonstrated comparable efficacy and safety...